dexamethasone + vincristine + pegylated-asparaginase + cytarabine + cyclophosphamide + doxorubicin + 6-mercaptopurine

This multi-agent chemotherapy regimen is a modified version of the Berlin-Frankfurt-Munster (BFM) backbone, specifically designed for the treatment of pediatric and adolescent patients with newly diagnosed lymphoblastic lymphoma (LBL) or acute lymphoblastic leukemia (ALL). The combination integrates several classes of antineoplastic agents to target malignant lymphoblasts through multiple pathways: **dexamethasone** (a corticosteroid) induces apoptosis; **vincristine** (a vinca alkaloid) inhibits microtubule polymerization to arrest mitosis; **pegylated-asparaginase** (pegaspargase) depletes L-asparagine, an essential amino acid for leukemic cells; **cytarabine** and **6-mercaptopurine** act as antimetabolites to inhibit DNA synthesis; **cyclophosphamide** serves as an alkylating agent to cause DNA cross-linking; and **doxorubicin** (an anthracycline) inhibits topoisomerase II and intercalates DNA. This intensive regimen aims to achieve high rates of complete remission and minimize the risk of central nervous system involvement and systemic relapse.

Other names

Modified BFM protocolModified Berlin-Frankfurt-Munster regimenBFM-95 modified regimenBFM95 modified regimenBFM 95 modified regimen